US6685940B2
(en)
*
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
US5783186A
(en)
*
|
1995-12-05 |
1998-07-21 |
Amgen Inc. |
Antibody-induced apoptosis
|
IL126303A
(en)
*
|
1996-03-27 |
2002-05-23 |
Genentech Inc |
ErbB3 ANTIBODIES
|
US5968511A
(en)
*
|
1996-03-27 |
1999-10-19 |
Genentech, Inc. |
ErbB3 antibodies
|
US20080220012A1
(en)
*
|
1996-05-15 |
2008-09-11 |
Ragupathy Madiyalakan |
Therapeutic Compositions that alter the immune response
|
CA2253602A1
(en)
*
|
1996-05-15 |
1997-11-20 |
Altarex Corp. |
Method and composition for reconforming multi-epitopic antigens to initiate an immune response
|
US8038994B2
(en)
*
|
1996-05-15 |
2011-10-18 |
Quest Pharmatech Inc. |
Combination therapy for treating disease
|
US20060159688A1
(en)
*
|
1996-05-15 |
2006-07-20 |
Ragupathy Madiyalakan |
Method for diagnosing efficacy of xenotypic antibody therapy
|
EP1106183A3
(en)
*
|
1996-10-18 |
2001-09-12 |
Genentech, Inc. |
Antibodies to erbB2 and their therapeutic uses
|
US7371376B1
(en)
|
1996-10-18 |
2008-05-13 |
Genentech, Inc. |
Anti-ErbB2 antibodies
|
US6270980B1
(en)
|
1997-06-05 |
2001-08-07 |
Idun Pharmaceuticals, Inc. |
Rapid methods for identifying modifiers of cellular apoptosis activity
|
ZA9811162B
(en)
*
|
1997-12-12 |
2000-06-07 |
Genentech Inc |
Treatment with anti-ERBB2 antibodies.
|
ES2308836T3
(es)
*
|
1998-03-27 |
2008-12-01 |
Genentech, Inc. |
Sinergia de los anticuerpos anti-her-2 y de los ligands para l'apo-2.
|
FR2780062B1
(fr)
*
|
1998-06-17 |
2000-07-28 |
Rhone Poulenc Rorer Sa |
Anticorps monoclonaux diriges contre la proteine g3bp, et leurs utilisations
|
US7393823B1
(en)
*
|
1999-01-20 |
2008-07-01 |
Oregon Health And Science University |
HER-2 binding antagonists
|
US7396810B1
(en)
*
|
2000-08-14 |
2008-07-08 |
Oregon Health Sciences University |
Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
|
US7625859B1
(en)
*
|
2000-02-16 |
2009-12-01 |
Oregon Health & Science University |
HER-2 binding antagonists
|
CA2357525A1
(en)
|
1999-01-27 |
2000-08-03 |
Cornell Research Foundation, Inc. |
Treating cancers associated with overexpression of her-2/neu
|
CA2368017A1
(en)
*
|
1999-04-06 |
2000-10-12 |
Genentech, Inc. |
Use of erbb receptor ligands in treating diabetes
|
US20030086924A1
(en)
*
|
1999-06-25 |
2003-05-08 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
CN101121021B
(zh)
|
1999-06-25 |
2011-12-07 |
杰南技术公司 |
人源化抗ErbB2抗体及用抗ErbB2抗体进行的治疗
|
US7041292B1
(en)
*
|
1999-06-25 |
2006-05-09 |
Genentech, Inc. |
Treating prostate cancer with anti-ErbB2 antibodies
|
US20040013667A1
(en)
*
|
1999-06-25 |
2004-01-22 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
ES2282120T3
(es)
*
|
1999-06-25 |
2007-10-16 |
Genentech, Inc. |
Tratamiento del cancer de prostata con anticuerpos anti-erbb2.
|
DK2283866T3
(en)
|
1999-06-25 |
2015-05-18 |
Genentech Inc |
METHODS OF TREATMENT USING ANTI-ERBB ANTIBODY-MAYTANSINOID CONJUGATES
|
US6949245B1
(en)
*
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
CA2382100A1
(en)
|
1999-08-27 |
2001-03-08 |
Genentech, Inc. |
Dosages for treatment with anti-erbb2 antibodies
|
EP1229934B1
(en)
|
1999-10-01 |
2014-03-05 |
Immunogen, Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
US20080124327A1
(en)
*
|
1999-10-08 |
2008-05-29 |
Arius Research, Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD44
|
US7256271B2
(en)
|
2003-01-21 |
2007-08-14 |
Arius Research Inc. |
Cancerous disease modifying antibodies
|
US6657048B2
(en)
*
|
1999-10-08 |
2003-12-02 |
Arius Research, Inc. |
Individualized anti-cancer antibodies
|
US6794494B1
(en)
|
2003-04-14 |
2004-09-21 |
Arius Research, Inc. |
Cancerous disease modifying antibodies
|
US8071072B2
(en)
*
|
1999-10-08 |
2011-12-06 |
Hoffmann-La Roche Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD44
|
US7442776B2
(en)
*
|
1999-10-08 |
2008-10-28 |
Young David S F |
Cancerous disease modifying antibodies
|
US7947496B2
(en)
*
|
1999-10-08 |
2011-05-24 |
Hoffmann-La Roche Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD44
|
US20040105816A1
(en)
*
|
1999-10-08 |
2004-06-03 |
Young David S. F. |
Cancerous disease modifying antibodies
|
US7252821B2
(en)
|
1999-10-08 |
2007-08-07 |
Arius Research Inc. |
Cancerous disease modifying antibodies
|
US8048416B2
(en)
*
|
1999-10-08 |
2011-11-01 |
Hoffmann-La Roche Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD44
|
US20040001789A1
(en)
*
|
1999-10-08 |
2004-01-01 |
Young David S. F. |
Cytotoxicity mediation of cells evidencing surface expression of gp96 or precursors thereof
|
US7419792B2
(en)
*
|
1999-10-08 |
2008-09-02 |
Arius Research Inc. |
Laminin Receptor 1 Precursor Protein (37LRP) epitope delineated by an Hepatocellular carcinoma specific antibody
|
US20050100542A1
(en)
*
|
1999-10-08 |
2005-05-12 |
Young David S. |
Cytotoxicity mediation of cells evidencing surface expression of CD44
|
US20090004103A1
(en)
*
|
1999-10-08 |
2009-01-01 |
Young David S F |
Cytotoxicity mediation of cells evidencing surface expression of CD44
|
US6180357B1
(en)
*
|
1999-10-08 |
2001-01-30 |
Arius Research, Inc. |
Individualized patient-specific anti-cancer antibodies
|
US7189397B2
(en)
*
|
1999-10-08 |
2007-03-13 |
Arius Research Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD44
|
EP1118334A1
(en)
*
|
2000-01-11 |
2001-07-25 |
Aventis Behring Gesellschaft mit beschränkter Haftung |
Method for the production of conjugates and uses thereof for the prevention and treatment of allergic reactions and autoimmune diseases
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
US6632979B2
(en)
|
2000-03-16 |
2003-10-14 |
Genentech, Inc. |
Rodent HER2 tumor model
|
HUP0300369A2
(hu)
|
2000-04-11 |
2003-06-28 |
Genentech, Inc. |
Többértékű antitestek és alkalmazásuk
|
AU2001259271A1
(en)
*
|
2000-04-28 |
2001-11-12 |
Millennium Pharmaceuticals, Inc. |
14094, a novel human trypsin family member and uses thereof
|
KR101135233B1
(ko)
|
2000-05-19 |
2012-04-12 |
제넨테크, 인크. |
ErbB 길항제에 의한 암 치료요법에 대한 효과적인 반응의 가능성을 개선시키기 위한 유전자 검출 분석
|
ES2281437T3
(es)
*
|
2000-08-22 |
2007-10-01 |
Agensys, Inc. |
Acido nucleico y proteina correspondiente denominada 158p1d7 util para el tratamiento y la deteccion del cancer de vejiga y otros canceres.
|
US7358353B2
(en)
*
|
2000-08-22 |
2008-04-15 |
Agensys, Inc. |
Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
|
US7442777B2
(en)
*
|
2000-11-29 |
2008-10-28 |
Arius Research Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD63
|
US7009040B2
(en)
*
|
2003-01-21 |
2006-03-07 |
Arius Research, Inc. |
Cancerous disease modifying antibodies
|
US7361343B2
(en)
*
|
2003-01-21 |
2008-04-22 |
Arius Research Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD63
|
US7431923B2
(en)
*
|
2005-01-03 |
2008-10-07 |
Arius Research Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD63
|
US20060210474A1
(en)
*
|
2000-11-29 |
2006-09-21 |
Young David S |
Cytotoxicity mediation of cells evidencing surface expression of CD63
|
US7534429B2
(en)
*
|
2000-11-29 |
2009-05-19 |
Hoffmann-La Roche Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD63
|
WO2002063037A2
(en)
*
|
2001-02-02 |
2002-08-15 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Method for identifying functional nucleic acids
|
US20050069549A1
(en)
|
2002-01-14 |
2005-03-31 |
William Herman |
Targeted ligands
|
AU2003216482A1
(en)
*
|
2002-03-01 |
2003-09-16 |
Exelixis, Inc. |
MSRAs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
|
US8658773B2
(en)
|
2011-05-02 |
2014-02-25 |
Immunomedics, Inc. |
Ultrafiltration concentration of allotype selected antibodies for small-volume administration
|
EP2289942B1
(en)
*
|
2002-04-10 |
2013-07-31 |
Genentech, Inc. |
Anti-HER2 antibody variants
|
JP2005522483A
(ja)
*
|
2002-04-11 |
2005-07-28 |
アルタレックス メディカル コーポレーション |
結合剤及び腫瘍細胞をターゲティングする際のそれらの使用
|
US20050276812A1
(en)
|
2004-06-01 |
2005-12-15 |
Genentech, Inc. |
Antibody-drug conjugates and methods
|
PL214010B1
(pl)
*
|
2002-07-15 |
2013-06-28 |
Genentech Inc |
Rekombinowane humanizowane przeciwcialo 2C4 i zastosowanie tego przeciwciala
|
DK2314629T4
(da)
|
2002-07-18 |
2023-02-06 |
Merus Nv |
Rekombinant produktion af blandinger af antistoffer
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
WO2004048525A2
(en)
*
|
2002-11-21 |
2004-06-10 |
Genentech, Inc. |
Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies
|
US7175846B2
(en)
*
|
2003-01-21 |
2007-02-13 |
Arius Research Inc. |
Cancerous disease modifying antibodies
|
US7488475B2
(en)
|
2003-01-21 |
2009-02-10 |
Arius Research, Inc. |
Antibody therapy of tumors
|
US7468254B2
(en)
*
|
2003-01-21 |
2008-12-23 |
Arius Research Inc. |
Cytotoxicity mediation of cells evidencing surface expression of MCSP
|
US7361342B2
(en)
*
|
2003-01-21 |
2008-04-22 |
Arius Research Inc. |
Cancerous disease modifying antibodies
|
US7393531B2
(en)
*
|
2003-01-21 |
2008-07-01 |
Arius Research Inc. |
Cytotoxicity mediation of cells evidencing surface expression of MCSP
|
US7399835B2
(en)
*
|
2004-02-26 |
2008-07-15 |
Arius Research Inc. |
Cancerous disease modifying antibodies
|
US7195764B2
(en)
|
2003-04-14 |
2007-03-27 |
Arius Research Inc. |
Cancerous disease modifying antibodies
|
US20080213169A1
(en)
*
|
2003-04-14 |
2008-09-04 |
Arius Research, Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD59
|
US20060140963A1
(en)
*
|
2003-04-14 |
2006-06-29 |
Arius Research, Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD59
|
US20080025977A1
(en)
*
|
2003-04-14 |
2008-01-31 |
Arius Research, Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD59
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
ES2408582T3
(es)
|
2003-05-30 |
2013-06-21 |
Merus B.V. |
Biblioteca de Fab para la preparación de una mezcla de anticuerpos
|
US20050008649A1
(en)
*
|
2003-06-02 |
2005-01-13 |
University Of Miami |
Chimeric molecules and methods of use
|
US20050232931A1
(en)
*
|
2003-06-13 |
2005-10-20 |
Oncomax Acquisition Corp. |
Preparation and application of anti-tumor bifunctional fusion proteins
|
US20040254108A1
(en)
*
|
2003-06-13 |
2004-12-16 |
Jing Ma |
Preparation and application of anti-tumor bifunctional fusion proteins
|
WO2005017107A2
(en)
|
2003-07-18 |
2005-02-24 |
Amgen Inc. |
Specific binding agents to hepatocyte growth factor
|
US20050027106A1
(en)
*
|
2003-07-28 |
2005-02-03 |
Young David S. F. |
Cancerous disease modifying antibodies
|
AU2004263538B2
(en)
*
|
2003-08-08 |
2009-09-17 |
Immunomedics, Inc. |
Bispecific antibodies for inducing apoptosis of tumor and diseased cells
|
CN107213469A
(zh)
|
2003-11-06 |
2017-09-29 |
西雅图基因公司 |
能够与配体偶联的单甲基缬氨酸化合物
|
ES2646560T3
(es)
|
2004-01-20 |
2017-12-14 |
Merus N.V. |
Mezclas de proteínas de unión
|
US7348413B2
(en)
*
|
2004-02-26 |
2008-03-25 |
Arius Research Inc. |
Cancerous disease modifying antibodies
|
US20050255041A1
(en)
*
|
2004-05-13 |
2005-11-17 |
Arius Research, Inc. |
Cancerous disease modifying antibodies
|
SV2006002143A
(es)
*
|
2004-06-16 |
2006-01-26 |
Genentech Inc |
Uso de un anticuerpo para el tratamiento del cancer resistente al platino
|
AU2005265163B2
(en)
|
2004-06-18 |
2009-10-01 |
Ambrx, Inc. |
Novel antigen-binding polypeptides and their uses
|
UA90480C2
(uk)
*
|
2004-07-22 |
2010-05-11 |
Джэнэнтэк, Инк. |
Фармацевтична композиція, що має протипухлинну активність, яка включає антитіло до her2
|
AU2005285347A1
(en)
*
|
2004-08-19 |
2006-03-23 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
CA2521973C
(en)
*
|
2004-09-29 |
2013-12-10 |
Tir Systems Ltd. |
System and method for controlling luminaires
|
CA2583230A1
(en)
*
|
2004-10-05 |
2006-04-20 |
Oregon Health And Science University |
Compositions and methods for treating disease
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
JP2008523073A
(ja)
*
|
2004-12-07 |
2008-07-03 |
ジェネンテック・インコーポレーテッド |
Her阻害剤を用いた治療のための患者の選択
|
US20090298195A1
(en)
|
2005-01-05 |
2009-12-03 |
F-Star Biotechnologische Forschungs-Und Entwicklun Gseges M.B.H. |
Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
|
CN101141981A
(zh)
|
2005-01-21 |
2008-03-12 |
健泰科生物技术公司 |
Her抗体的固定剂量给药
|
CN101115836A
(zh)
*
|
2005-02-09 |
2008-01-30 |
健泰科生物技术公司 |
用基质金属蛋白酶拮抗剂抑制her2脱落
|
ES2440481T3
(es)
*
|
2005-02-23 |
2014-01-29 |
Genentech, Inc. |
Prolongación del tiempo hasta la progresión de la enfermedad o supervivencia en pacientes de cáncer de ovario usando pertuzumab
|
WO2006096861A2
(en)
*
|
2005-03-08 |
2006-09-14 |
Genentech, Inc. |
METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs)
|
JP2006316040A
(ja)
|
2005-05-13 |
2006-11-24 |
Genentech Inc |
Herceptin(登録商標)補助療法
|
US7411046B2
(en)
|
2005-08-02 |
2008-08-12 |
Arius Research Inc |
Cancerous disease modifying antibodies
|
US7452978B2
(en)
*
|
2005-08-02 |
2008-11-18 |
Arius Research, Inc. |
Cancerous disease modifying antibodies
|
US7456258B2
(en)
|
2005-08-02 |
2008-11-25 |
Arius Research, Inc. |
Cancerous disease modifying antibodies
|
US7452979B2
(en)
|
2005-08-02 |
2008-11-18 |
Arius Research, Inc. |
Cancerous disease modifying antibodies
|
US7456259B2
(en)
|
2005-08-02 |
2008-11-25 |
Arius Research, Inc. |
Cancerous disease modifying antibodies
|
US7494648B2
(en)
*
|
2005-08-02 |
2009-02-24 |
Hoffmann-La Roche Inc. |
Cancerous disease modifying antibodies
|
FR2895086B1
(fr)
*
|
2005-12-16 |
2012-10-05 |
Lab Francais Du Fractionnement |
Potentialisation de l'apoptose par des anticorps monoclonaux
|
WO2007095745A1
(en)
|
2006-02-24 |
2007-08-30 |
Arius Research Inc. |
Cancerous disease modifying antibody 141205-02
|
US20080305104A1
(en)
*
|
2006-02-24 |
2008-12-11 |
Young David S F |
Cytotoxicity mediation of cells evidencing surface expression of TROP-2
|
EP1996699A4
(en)
|
2006-02-24 |
2009-02-25 |
Arius Res Inc |
ANTIBODIES THAT MODIFY CANCER DISEASES
|
US7420041B2
(en)
*
|
2006-02-24 |
2008-09-02 |
Arius Research Inc. |
Cytotoxicity mediation of cells evidencing surface expression of TROP-2
|
US20080213267A1
(en)
*
|
2006-02-24 |
2008-09-04 |
Arius Research, Inc. |
Cytotoxicity mediation of cells evidencing surface expression of TROP-2
|
AT503889B1
(de)
|
2006-07-05 |
2011-12-15 |
Star Biotechnologische Forschungs Und Entwicklungsges M B H F |
Multivalente immunglobuline
|
US20080089891A1
(en)
*
|
2006-07-26 |
2008-04-17 |
Arius Research, Inc. |
Cancerous disease modifying antibodies
|
DK2511301T3
(en)
|
2006-08-04 |
2018-03-12 |
Medimmune Ltd |
HUMAN ANTIBODIES AGAINST ERBB 2
|
CN101595213A
(zh)
*
|
2006-11-13 |
2009-12-02 |
霍夫曼-拉罗奇有限公司 |
修饰癌性疾病的抗体
|
CN101535470A
(zh)
*
|
2006-11-13 |
2009-09-16 |
霍夫曼-拉罗奇有限公司 |
修饰癌性疾病的抗体180706-01
|
US8129502B2
(en)
*
|
2006-11-13 |
2012-03-06 |
Hoffmann-La Roche Inc. |
Cancerous disease modifying antibodies
|
US20080206133A1
(en)
*
|
2007-01-23 |
2008-08-28 |
Young David S F |
Cancerous Disease Modifying Antibodies
|
US8003761B2
(en)
|
2007-01-23 |
2011-08-23 |
Hoffmann-La Roche Inc. |
Cancerous disease modifying antibodies
|
CL2008000614A1
(es)
*
|
2007-03-02 |
2008-09-05 |
Genentech Inc F Hoffmann La Ro |
Metodo para tratar un paciente con un tipo de cancer que expresa el receptor her3 a un nivel bajo mediante la administracion de un inhibidor de la dimerizacion de her.
|
US20080241137A1
(en)
*
|
2007-03-26 |
2008-10-02 |
Young David S F |
Cancerous disease modifying antibodies
|
MX2009011667A
(es)
*
|
2007-05-07 |
2009-11-10 |
Hoffmann La Roche |
Anticuerpos de modificacion de enfermedad cancerosa.
|
US20090304590A1
(en)
*
|
2007-05-29 |
2009-12-10 |
Wyeth |
Therapeutic compositions and methods
|
WO2008150485A2
(en)
*
|
2007-05-29 |
2008-12-11 |
Wyeth |
Erbb2 binding proteins and use thereof
|
US9551033B2
(en)
|
2007-06-08 |
2017-01-24 |
Genentech, Inc. |
Gene expression markers of tumor resistance to HER2 inhibitor treatment
|
SI2171090T1
(sl)
*
|
2007-06-08 |
2013-07-31 |
Genentech, Inc. |
Markerji genskega izraĹľanja tumorske odpornosti na HER2 inhibitorsko zdravljenje
|
US8921279B2
(en)
|
2007-06-26 |
2014-12-30 |
F-Star Biotechnologische Forschungs—und Entwicklungsges. m.b.H |
Display of binding agents
|
SG10202005450PA
(en)
|
2007-07-09 |
2020-07-29 |
Genentech Inc |
Prevention of disulfide bond reduction during recombinant production of polypeptides
|
ES2381788T3
(es)
|
2007-07-16 |
2012-05-31 |
Genentech, Inc. |
Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
|
AU2008276128B2
(en)
|
2007-07-16 |
2013-10-10 |
Genentech, Inc. |
Humanized anti-CD79b antibodies and immunoconjugates and methods of use
|
AU2008341050B2
(en)
*
|
2007-12-26 |
2013-10-24 |
Vaccinex, Inc. |
Anti-C35 antibody combination therapies and methods
|
EP2237797A4
(en)
|
2008-01-03 |
2012-11-07 |
Scripps Research Inst |
TARGETING ANTIBODIES BY MODULAR RECOGNITION DOMAIN
|
US8557242B2
(en)
|
2008-01-03 |
2013-10-15 |
The Scripps Research Institute |
ERBB2 antibodies comprising modular recognition domains
|
US8574577B2
(en)
|
2008-01-03 |
2013-11-05 |
The Scripps Research Institute |
VEGF antibodies comprising modular recognition domains
|
US8557243B2
(en)
|
2008-01-03 |
2013-10-15 |
The Scripps Research Institute |
EFGR antibodies comprising modular recognition domains
|
US8454960B2
(en)
|
2008-01-03 |
2013-06-04 |
The Scripps Research Institute |
Multispecific antibody targeting and multivalency through modular recognition domains
|
US20090191197A1
(en)
*
|
2008-01-28 |
2009-07-30 |
Young David S F |
Cancerous disease modifying antibodies
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
IL287292B
(en)
|
2008-01-31 |
2022-09-01 |
Genentech Inc |
and fusion antibody-drug-cd79b engineered antibodies cysteine-
|
AR070865A1
(es)
|
2008-03-18 |
2010-05-12 |
Genentech Inc |
Combinaciones de un conjugado anticuerpo- farmaco anti- her2 y agentes quimioterapeuticos y los metodos de uso
|
WO2009124381A1
(en)
*
|
2008-04-10 |
2009-10-15 |
F. Hoffmann-La Roche Ag |
An anti-cancer cytotoxic monoclonal antibody
|
EP3056513A1
(en)
|
2008-04-11 |
2016-08-17 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
|
EP2113255A1
(en)
|
2008-05-02 |
2009-11-04 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Cytotoxic immunoglobulin
|
CA2724782A1
(en)
*
|
2008-05-19 |
2009-11-26 |
Takeda Pharmaceutical Company Limited |
An anti-cancer cytotoxic monoclonal antibody
|
BRPI0812682A2
(pt)
|
2008-06-16 |
2010-06-22 |
Genentech Inc |
tratamento de cáncer de mama metastático
|
CA2731129A1
(en)
*
|
2008-07-17 |
2010-01-21 |
Helen P. Findlay |
Cancerous disease modifying antibodies
|
TWI440469B
(zh)
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
WO2010051502A2
(en)
*
|
2008-10-31 |
2010-05-06 |
Biogen Idec Ma Inc. |
Light targeting molecules and uses thereof
|
CA2749501C
(en)
|
2009-02-13 |
2017-01-10 |
Immunomedics, Inc. |
Immunoconjugates with an intracellularly-cleavable linkage
|
CN102356092B
(zh)
|
2009-03-20 |
2014-11-05 |
霍夫曼-拉罗奇有限公司 |
双特异性抗-her抗体
|
SG10201507044PA
(en)
|
2009-05-29 |
2015-10-29 |
Hoffmann La Roche |
Modulators for her2 signaling in her2 expressing patients with gastric cancer
|
WO2011004899A1
(en)
|
2009-07-06 |
2011-01-13 |
Takeda Pharmaceutical Company Limited |
Cancerous disease modifying antibodies
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
RU2639288C2
(ru)
|
2009-08-11 |
2017-12-20 |
Дженентек, Инк. |
Получение белков в культуральных средах без глутамина
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
IN2012DN01663A
(xx)
|
2009-09-16 |
2015-06-05 |
Immunomedics Inc |
|
CA2782194C
(en)
|
2009-12-02 |
2018-01-16 |
Immunomedics, Inc. |
Combination of radiolabelled antibodies (rait) and antibody-drug conjugates (adc) for treatment of pancreatic cancer
|
KR20130000384A
(ko)
|
2010-02-18 |
2013-01-02 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
뉴레귤린 길항제 및 암의 치료에서의 그의 용도
|
CA2796180A1
(en)
|
2010-04-15 |
2011-10-20 |
Alper Biotech, Llc |
Monoclonal antibodies against her2 antigens, and uses therefor
|
US9328024B2
(en)
|
2010-04-29 |
2016-05-03 |
The Regents Of The University Of California |
Application of high toughness, low viscosity nano-molecular resin for reinforcing pothole patching materials in asphalt and concrete base pavement
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
EP2407487A1
(en)
|
2010-07-14 |
2012-01-18 |
F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. |
Multispecific modular antibody
|
US20120100166A1
(en)
|
2010-07-15 |
2012-04-26 |
Zyngenia, Inc. |
Ang-2 Binding Complexes and Uses Thereof
|
US20130245233A1
(en)
|
2010-11-24 |
2013-09-19 |
Ming Lei |
Multispecific Molecules
|
RU2658504C9
(ru)
|
2010-11-30 |
2018-08-21 |
Чугаи Сейяку Кабусики Кайся |
Антигенсвязывающая молекула, способная многократно связываться с множеством антигенных молекул
|
CA2820095C
(en)
|
2010-12-21 |
2019-02-26 |
F. Hoffmann-La Roche Ag |
Isoform enriched antibody preparation and method for obtaining it
|
WO2012085111A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
MX352889B
(es)
|
2011-02-25 |
2017-12-13 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo de fc especifico para fcyriib.
|
WO2012122512A1
(en)
|
2011-03-10 |
2012-09-13 |
Hco Antibody, Inc. |
Recombinant production of mixtures of single chain antibodies
|
AU2012258637B2
(en)
|
2011-05-24 |
2017-07-20 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
EP2546268A1
(en)
|
2011-07-13 |
2013-01-16 |
F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. |
Internalising immunoglobulin
|
EP2744824A1
(en)
|
2011-08-17 |
2014-06-25 |
F.Hoffmann-La Roche Ag |
Neuregulin antibodies and uses thereof
|
BR112014004762A2
(pt)
|
2011-08-31 |
2018-06-19 |
Genentech Inc |
métodos de determinação da sensibilidade de crescimento de célula tumoral á inibição por um inibidor de quinase de egfr, de identificação de um paciente com câncer que provavelmente irá se beneficiar do tratamento com um inibidor de efgr, de tratamento de um câncer em um paciente, de seleção de uma terapia para um paciente com câncer e de determinação de superexpressão de gene erbb2 em uma célula
|
JP6322411B2
(ja)
|
2011-09-30 |
2018-05-09 |
中外製薬株式会社 |
複数の生理活性を有する抗原の消失を促進する抗原結合分子
|
WO2013063229A1
(en)
*
|
2011-10-25 |
2013-05-02 |
The Regents Of The University Of Michigan |
Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
|
BR112014012979A2
(pt)
|
2011-11-30 |
2020-10-20 |
Genentech, Inc. |
mutações erbb3 em câncer
|
EP2788500A1
(en)
|
2011-12-09 |
2014-10-15 |
F.Hoffmann-La Roche Ag |
Identification of non-responders to her2 inhibitors
|
AU2013240261A1
(en)
|
2012-03-27 |
2014-09-18 |
Genentech, Inc. |
Diagnosis and treatments relating to HER3 inhibitors
|
PT2838918T
(pt)
|
2012-04-20 |
2019-08-23 |
Merus Nv |
Métodos e meios para a produção de moléculas heterrodiméricas do tipo ig
|
EP2885002A4
(en)
|
2012-08-14 |
2016-04-20 |
Ibc Pharmaceuticals Inc |
BISPECIFIC ANTIBODIES REDIRECTED AGAINST T CELLS FOR THE TREATMENT OF DISEASES
|
KR102355959B1
(ko)
|
2012-08-23 |
2022-01-27 |
어젠시스 인코포레이티드 |
158p1d7 단백질에 결합하는 항체 약물 컨쥬게이트(adc)
|
CN105121472A
(zh)
|
2012-10-30 |
2015-12-02 |
埃斯佩兰斯医药公司 |
抗体/药物缀合物及其使用方法
|
RU2692773C2
(ru)
|
2012-11-30 |
2019-06-27 |
Ф.Хоффманн-Ля Рош Аг |
Идентификация пациентов, нуждающихся в совместной терапии с использованием ингибитора pd-l1
|
WO2014092804A1
(en)
|
2012-12-13 |
2014-06-19 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
|
CN105451767B
(zh)
|
2013-03-15 |
2019-10-18 |
泽恩格尼亚股份有限公司 |
多价和单价多特异性复合物及其用途
|
KR101453462B1
(ko)
|
2013-05-16 |
2014-10-23 |
앱클론(주) |
Her2에 특이적으로 결합하는 항체
|
WO2015126548A1
(en)
|
2014-02-21 |
2015-08-27 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to trop-2 expressing cells
|
CN106029098A
(zh)
|
2014-02-25 |
2016-10-12 |
免疫医疗公司 |
人源化rfb4抗cd22抗体
|
BR112016023500B1
(pt)
|
2014-04-10 |
2024-04-30 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Ácido nucleico que codifica um receptor quimérico, método para a preparação de uma célula hospedeira e usos do mesmo
|
KR20160143808A
(ko)
|
2014-04-11 |
2016-12-14 |
메디뮨 엘엘씨 |
이중특이적 her2 항체
|
EP3131584B1
(en)
|
2014-04-16 |
2022-01-12 |
Biocon Limited |
Stable protein formulations comprising a molar excess of sorbitol
|
WO2015200260A1
(en)
|
2014-06-24 |
2015-12-30 |
Immunomedics, Inc. |
Anti-histone therapy for vascular necrosis in severe glomerulonephritis
|
RS60349B8
(sr)
|
2014-09-23 |
2022-10-31 |
Hoffmann La Roche |
Postupak upotrebe anti-cd79b imunokonjugata
|
EP3204018B1
(en)
|
2014-10-07 |
2021-08-25 |
Immunomedics, Inc. |
Neoadjuvant use of antibody-drug conjugates
|
KR20180054923A
(ko)
|
2014-12-19 |
2018-05-24 |
추가이 세이야쿠 가부시키가이샤 |
항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
|
TW201809008A
(zh)
|
2014-12-19 |
2018-03-16 |
日商中外製藥股份有限公司 |
抗c5抗體及使用方法
|
EP3816179A3
(en)
|
2015-02-05 |
2021-08-04 |
Chugai Seiyaku Kabushiki Kaisha |
Fc region variant comprising a modified fcrn-binding domain
|
SG11201705093UA
(en)
|
2015-02-27 |
2017-07-28 |
Chugai Pharmaceutical Co Ltd |
Composition for treating il-6-related diseases
|
CN107428837A
(zh)
|
2015-04-22 |
2017-12-01 |
免疫医疗公司 |
循环trop‑2阳性癌细胞的分离、检测、诊断和/或鉴定
|
EP3303373B1
(en)
|
2015-05-30 |
2020-04-08 |
Molecular Templates, Inc. |
De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
|
JP2018524312A
(ja)
*
|
2015-06-17 |
2018-08-30 |
ジェネンテック, インコーポレイテッド |
抗her2抗体及び使用方法
|
PT3313443T
(pt)
|
2015-06-25 |
2023-08-30 |
Immunomedics Inc |
Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro
|
SI3316885T1
(sl)
|
2015-07-01 |
2021-09-30 |
Immunomedics, Inc. |
Imunokonjugati protitelo-SN-38 z linkerjem CL2A
|
WO2017027291A1
(en)
|
2015-08-07 |
2017-02-16 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Bispecific car t-cells for solid tumor targeting
|
WO2017110981A1
(en)
|
2015-12-25 |
2017-06-29 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-myostatin antibodies and methods of use
|
EP3454863A1
(en)
|
2016-05-10 |
2019-03-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combinations therapies for the treatment of cancer
|
TW202300168A
(zh)
|
2016-08-05 |
2023-01-01 |
日商中外製藥股份有限公司 |
Il-8相關疾病之治療用或預防用組成物
|
EP3551197B1
(en)
|
2016-12-12 |
2023-11-22 |
Seattle Children's Hospital (DBA Seattle Children's Research Institute) |
Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
|
PT3570884T
(pt)
|
2017-01-17 |
2020-11-24 |
Hoffmann La Roche |
Formulações subcutâneas de anticorpo do her2
|
US11608374B2
(en)
|
2017-01-30 |
2023-03-21 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-sclerostin antibodies and methods of use
|
US20210330801A1
(en)
|
2017-03-02 |
2021-10-28 |
Cadila Healthcare Limited |
Novel protein drug conjugate formulation
|
CN116531511A
(zh)
|
2017-03-02 |
2023-08-04 |
豪夫迈·罗氏有限公司 |
Her2阳性乳腺癌的辅助治疗
|
EP3620531A4
(en)
|
2017-05-02 |
2021-03-17 |
National Center of Neurology and Psychiatry |
METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
|
US20210179733A1
(en)
|
2017-11-14 |
2021-06-17 |
Green Cross Lab Cell Corporation |
Anti-her2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
|
US11649294B2
(en)
|
2017-11-14 |
2023-05-16 |
GC Cell Corporation |
Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
|
SG10201801219VA
(en)
|
2018-02-13 |
2019-09-27 |
Agency Science Tech & Res |
Anti-HER2 Antibodies
|
EP3573652A1
(en)
|
2018-04-17 |
2019-12-04 |
Molecular Templates, Inc. |
Her2-targeting molecules comprising de-immunized, shiga toxin a subunit scaffolds
|
EP3560945A1
(en)
|
2018-04-27 |
2019-10-30 |
F. Hoffmann-La Roche AG |
Methods for purification of polypeptides using polysorbates
|
IL300314A
(en)
|
2020-10-08 |
2023-04-01 |
Affimed Gmbh |
Coupling materials with triple specificity
|
WO2022239720A1
(ja)
|
2021-05-10 |
2022-11-17 |
公益財団法人川崎市産業振興財団 |
抗原への結合親和性を低減させた抗体
|
CA3216098A1
(en)
|
2021-07-30 |
2023-02-02 |
Uwe Reusch |
Duplexbodies
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
AU2022382368A1
(en)
|
2021-11-03 |
2024-05-02 |
Affimed Gmbh |
Bispecific cd16a binders
|